Top

25-09-2024 | Dupilumab | Review

ABCs of Biologics in Pediatric Eczema: An Updated Review on the Safety and Efficacy of Systemic Treatments for Pediatric Atopic Dermatitis and Future Directions

Authors: Sarah Kamsiah Zemlok, JiaDe Yu

Published in: Current Dermatology Reports

Abstract

Purpose of review

Expansion of systemic therapies has improved atopic dermatitis (AD) management in pediatric cohorts, however guidelines for use of these medications in children remain limited. This review aims to guide decision-making for selection and substitution of systemic therapies as well as anticipation of potential adverse effects for pediatric AD patients.

Recent findings

Currently, high-dose abrocitinib and any-dose upadacitinib exhibit the best clinical outcomes followed by dupilumab. Administration of scheduled live vaccines in dupilumab-treated children outweighs risks of deferred immunization, however vaccine safety and efficacy in dupilumab and future systemic AD therapies should be included in clinical trials.

Summary

Dupilumab has the broadest age-approval and best safety-efficacy and is thus the best first-choice systemic option for pediatric AD. Risks of dupilumab use include provisional guidance for administration of scheduled live vaccines in children and conjunctivitis, which may be mitigated with topical treatments or switching to an IL-13 inhibiting MAB such as tralokinumab or lebrikizumab.

Mikhaylov D, Ungar B, Renert-Yuval Y, Guttman-Yassky E. Oral Janus kinase inhibitors for atopic dermatitis. Annals Allergy Asthma Immunology. 2023;130(5):577–92. https://doi.org/10.1016/j.anai.2023.01.020.CrossRef

Zhao A, Pan C, Li M. Biologics and oral small-molecule inhibitors for treatment of pediatric atopic dermatitis: opportunities and challenges. Pediatr Invest. 2023;7(3):177–90. https://doi.org/10.1002/ped4.12400.CrossRef

Butala S, Paller AS. Biologics in the management of childhood atopic dermatitis. J Allergy Clin Immunol. 2023;151(3):681–5. https://doi.org/10.1016/j.jaci.2023.01.010.CrossRefPubMed

Amy S, Paller S, Butala. William Howe. Treatment of atopic dermatitis (Eczema). Uptodate; 2024.

Keam SJ. Lebrikizumab: first approval. Drugs. 2024;84(3):347–53. https://doi.org/10.1007/s40265-024-02000-z.CrossRefPubMed

Paller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. Am J Clin Dermatol. 2024;25(4):655–68. https://doi.org/10.1007/s40257-024-00859-y.CrossRefPubMedPubMedCentral

Geba GP, Li D, Xu M, et al. Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756–66. https://doi.org/10.1016/j.jaci.2022.08.026.CrossRefPubMed

Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019;80(1):158–e1671. https://doi.org/10.1016/j.jaad.2018.07.048.CrossRefPubMed

Siegfried EC, Wine Lee L, Spergel JM, et al. A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis. Pediatr Dermatol. 2024;41(2):204–9. https://doi.org/10.1111/pde.15518.CrossRefPubMed

10.

Lieberman JA, Chu DK, Ahmed T et al. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology. Annals of Allergy, Asthma & Immunology. Published online June 5, 2024. https://doi.org/10.1016/j.anai.2024.05.014

11.

Marshall GD, Tracy JM. Is it safe and effective to give live viral vaccines to patients on biologics? Annals of allergy, asthma, & immunology. Published online 2024. https://doi.org/10.1016/j.anai.2024.06.031

12.

Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022;86(3):628–36. https://doi.org/10.1016/j.jaad.2021.06.017.CrossRefPubMed

13.

Mickevicius T, Pink AE, Bhogal M, O’Brart D, Robbie SJ, Dupilumab-Induced. Tralokinumab-Induced, and Belantamab Mafodotin–Induced adverse ocular Events—Incidence, etiology, and management. Cornea. 2023;42(4):507. https://doi.org/10.1097/ICO.0000000000003162.CrossRefPubMed

14.

Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–47. https://doi.org/10.1016/j.jaad.2020.08.051.CrossRefPubMed

15.

Achten R, Dekkers C, Bakker D, et al. Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: preliminary case series. Clinical Experimental Allergy. 2023;53(5):586–9. https://doi.org/10.1111/cea.14305.CrossRefPubMed

16.

Bakker DS, Ariens LFM, van Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180(5):1248–9. https://doi.org/10.1111/bjd.17538.CrossRefPubMedPubMedCentral

17.

Bax CE, Khurana MC, Treat JR, Castelo-Soccio L, Rubin AI, McMahon PJ. New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis. Pediatr Dermatol. 2021;38(2):390–4. https://doi.org/10.1111/pde.14499.CrossRefPubMed

18.

Darabi K, Hostetler SG, Bechtel MA, Zirwas M. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60(1):125–36. https://doi.org/10.1016/j.jaad.2008.07.058.CrossRefPubMed

19.

Leonard A, Guttman-Yassky E. The Unique Molecular Signatures of Contact Dermatitis and implications for treatment. Clin Rev Allerg Immunol. 2019;56(1):1–8. https://doi.org/10.1007/s12016-018-8685-0.CrossRef

20.

Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–49. https://doi.org/10.1111/bjd.19574.CrossRefPubMed

21.

Study Details | Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 | ClinicalTrials.gov. Accessed July 21. 2024. https://clinicaltrials.gov/study/NCT03556592?intr=tralokinumab&cond=Atopic%20Dermatitis&rank=19

22.

Study Details | Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 | ClinicalTrials.gov. Accessed July 21. 2024. https://clinicaltrials.gov/study/NCT03761537?intr=tralokinumab&cond=Atopic%20Dermatitis&rank=10#study-overview

23.

Paller AS, Flohr C, Cork M, et al. Efficacy and safety of Tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatology. 2023;159(6):596–605. https://doi.org/10.1001/jamadermatol.2023.0627.CrossRefPubMedPubMedCentral

24.

Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815–24. https://doi.org/10.1016/j.jaad.2022.07.019.CrossRefPubMed

25.

Merola JF, Bagel J, Almgren P, et al. Tralokinumab does not impact vaccine-induced immune responses: results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2021;85(1):71–8. https://doi.org/10.1016/j.jaad.2021.03.032.CrossRefPubMed

26.

Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of Lebrikizumab for Moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–91. https://doi.org/10.1056/NEJMoa2206714.CrossRefPubMed

27.

Study Details | A Study of Lebrikizumab (LY3650150) in Participants 6 Months to < 18 Years of Age With Moderate-to-Severe Atopic Dermatitis | ClinicalTrials.gov. Accessed July 20. 2024. https://clinicaltrials.gov/study/NCT05559359?intr=Lebrikizumab&cond=Atopic%20Dermatitis&rank=17

28.

Paller AS, Flohr C, Eichenfield LF, et al. Safety and Efficacy of Lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-Week, Open-Label, phase 3 study. Dermatol Ther (Heidelb). 2023;13(7):1517–34. https://doi.org/10.1007/s13555-023-00942-y.CrossRefPubMed

29.

Igarashi A, Katsunuma T, Matsumura T, Komazaki H, for the Nemolizumab-JP04 Study Group. Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. Br J Dermatol. 2024;190(1):20–8. https://doi.org/10.1093/bjd/ljad268.CrossRef

30.

Sidbury R, Alpizar S, Laquer V, et al. Pharmacokinetics, Safety, Efficacy, and Biomarker profiles during Nemolizumab Treatment of atopic dermatitis in adolescents. Dermatol Ther (Heidelb). 2022;12(3):631–42. https://doi.org/10.1007/s13555-021-00678-7.CrossRefPubMed

31.

Guttman-Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(2):482–e4937. https://doi.org/10.1016/j.jaci.2018.11.053.CrossRefPubMed

32.

Rewerska B, Sher LD, Alpizar S, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis. J Allergy Clin Immunology: Global. 2024;3(1). https://doi.org/10.1016/j.jacig.2023.100195.

33.

Weidinger S, Bieber T, Cork MJ, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol. 2023;189(5):531–9. https://doi.org/10.1093/bjd/ljad240.CrossRefPubMed

34.

Guttman-Yassky E, Simpson EL, Reich K, et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023;401(10372):204–14. https://doi.org/10.1016/S0140-6736(22)02037-2.CrossRefPubMed

35.

Abrocitinib. Drug information - UpToDate. Accessed July 19, 2024. https://www-uptodate-com.online.uchc.edu/contents/abrocitinib-drug-information?search=abrocitinib&source=search_result&selectedTitle=1%7E9&usage_type=panel&kp_tab=drug_general&display_rank=1#F57957821

36.

Upadacitinib. Drug information - UpToDate. Accessed July 19, 2024. https://www-uptodate-com.online.uchc.edu/contents/upadacitinib-drug-information?source=auto_suggest&selectedTitle=1~1---1~4---rinvoq&search=rinvoq#F53551384

37.

Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of Abrocitinib in patients with moderate-to-severe atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatology. 2020;156(8):863–73. https://doi.org/10.1001/jamadermatol.2020.1406.CrossRefPubMed

38.

Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–66. https://doi.org/10.1016/S0140-6736(20)30732-7.CrossRefPubMed

39.

Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of Abrocitinib in Combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN Randomized Clinical Trial. JAMA Dermatology. 2021;157(10):1165–73. https://doi.org/10.1001/jamadermatol.2021.2830.CrossRefPubMed

40.

Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and Safety of Upadacitinib Treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up Randomized clinical trials. JAMA Dermatology. 2023;159(5):526–35. https://doi.org/10.1001/jamadermatol.2023.0391.CrossRefPubMedPubMedCentral

41.

Zhang Y, Jing D, Cheng J, Chen X, Shen M, Liu H. The efficacy and safety of IL-13 inhibitors in atopic dermatitis: a systematic review and meta-analysis. Front Immunol. 2022;13. https://doi.org/10.3389/fimmu.2022.923362.

42.

Drucker AM, Lam M, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: Living Systematic Review and Network Meta-Analysis Update. JAMA Dermatology. Published Online July. 2024;17. https://doi.org/10.1001/jamadermatol.2024.2192.

43.

Guyot P, Xu Y, Praestgaard A, Freemantle N, Rossi AB, Brad Shumel, Gaëlle Bégo-Le-Bagousse, Wang Z, Noonan K. Mike Bastian. 682- Dupilumab demonstrates higher likelihood of maintaining efficacy outcomes compared with lebrikizumab in monotherapy at week 52: results from a placebo-adjusted indirect comparison analysis. British Journal of Dermatology. 2024;191(Supplement_2). https://doi-org.online.uchc.edu/https://doi.org/10.1093/bjd/ljae266.056

44.

Torres T, Sohrt Petersen A, Ivens U, Bosch Vilaro A, Stinson J, Carrascosa JM. Matching-adjusted Indirect comparison of the efficacy at Week 32 of Tralokinumab and Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14(4):983–92. https://doi.org/10.1007/s13555-024-01143-x.CrossRefPubMed

45.

Schlösser AR, Shareef M, Olydam J, Nijsten TEC, Hijnen DJ. Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clin Exp Dermatol. 2023;48(5):510–7. https://doi.org/10.1093/ced/llad038.CrossRefPubMed

46.

Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a Living Systematic Review and Network Meta-Analysis. JAMA Dermatology. 2022;158(5):523–32. https://doi.org/10.1001/jamadermatol.2022.0455.CrossRefPubMedPubMedCentral

47.

Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of Upadacitinib vs Dupilumab in adults with moderate-to-severe atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatology. 2021;157(9):1047–55. https://doi.org/10.1001/jamadermatol.2021.3023.CrossRefPubMedPubMedCentral

48.

Patruno C, Fabbrocini G, Potestio L, Genco L, Napolitano M. Real-life efficacy and safety of upadacitinib in adolescents with moderate‐to‐severe atopic dermatitis unresponsive to dupilumab: a case series. | J Eur Acad Dermatology Venereol | EBSCOhost. https://doi.org/10.1111/jdv.19011

49.

Simpson EL, Silverberg JI, Thyssen JP, et al. Efficacy and safety of Abrocitinib in patients with severe and/or difficult-to-treat atopic dermatitis: a Post Hoc Analysis of the Randomized phase 3 JADE COMPARE Trial. Am J Clin Dermatol. 2023;24(4):609–21. https://doi.org/10.1007/s40257-023-00785-5.CrossRefPubMedPubMedCentral

50.

Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–82. https://doi.org/10.1016/S0140-6736(22)01199-0.CrossRefPubMed

51.

Gao Q, Zhao Y, Zhang J. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Heliyon. 2023;9(6). https://doi.org/10.1016/j.heliyon.2023.e16704.

52.

Gori N, Chiricozzi A, Malvaso D, et al. Successful combination of systemic agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy. Dermatology. 2021;237(4):535–41. https://doi.org/10.1159/000512890.CrossRefPubMed

Title: ABCs of Biologics in Pediatric Eczema: An Updated Review on the Safety and Efficacy of Systemic Treatments for Pediatric Atopic Dermatitis and Future Directions
Authors: Sarah Kamsiah Zemlok
JiaDe Yu
Publication date: 25-09-2024
Publisher: Springer US
Keywords: Dupilumab
Atopic Dermatitis
Janus Kinase Inhibitors
Conjunctivitis
Systemic Therapy
Systemic Therapy
Published in: Current Dermatology Reports
Electronic ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-024-00455-7

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

ABCs of Biologics in Pediatric Eczema: An Updated Review on the Safety and Efficacy of Systemic Treatments for Pediatric Atopic Dermatitis and Future Directions

Abstract

Purpose of review

Recent findings

Summary

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content